Search

CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

Jobs

Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Eye drop ingredient could be used to combat blood cancer

A drug for wet AMD has shown promise as a potential treatment for acute myeloid leukaemia

A patient receiving eye drops

A compound that was in development for the treatment of wet age-related macular degeneration could potentially be used to combat an aggressive form of blood cancer.

Writing in Nature Communications, scientists describe experiments where patient-derived acute myeloid leukaemia cells were transplanted into immunocompromised mice.

The mice were then treated with the compound, SPHINX31, which was originally formulated to target retinal neovascular disease.

Scientists found that the growth of cancer cells was inhibited in the mice following treatment and the mice did not show any noticeable side effects.

Dr George Vassiliou highlighted that the compound restricted the growth of acute myeloid leukaemia without harming healthy cells.

“This shows promise as a potential approach for treating this aggressive leukaemia in humans,” he emphasised. 

Advertisement